Cargando…

Liposomal amphotericin B as a treatment for human leishmaniasis

INTRODUCTION: Leishmaniasis is a parasitic disease transmitted by phlebotomine sandflies. Between 700,000 and 1.2 million cases of cutaneous leishmaniasis and between 200,000 and 400,000 cases of visceral leishmaniasis (VL), which is fatal if left untreated, occur annually worldwide. Liposomal ampho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balasegaram, Manica, Ritmeijer, Koert, Lima, Maria Angeles, Burza, Sakib, Ortiz Genovese, Gemma, Milani, Barbara, Gaspani, Sara, Potet, Julien, Chappuis, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Informa UK, Ltd. 2012
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518293/ https://www.ncbi.nlm.nih.gov/pubmed/23167833 http://dx.doi.org/10.1517/14728214.2012.748036

Ejemplares similares

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India
por: Burza, Sakib, et al.
Publicado: (2014)

Tuberculosis in Visceral Leishmaniasis-Human Immunodeficiency Virus Coinfection: An Evidence Gap in Improving Patient Outcomes?
por: van Griensven, Johan, et al.
Publicado: (2018)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

Treatment options for second-stage gambiense human African trypanosomiasis
por: Eperon, Gilles, et al.
Publicado: (2014)

Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome)
por: Burza, Sakib, et al.
Publicado: (2014)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018)

Human African Trypanosomiasis in Areas without Surveillance
por: Chappuis, François, et al.
Publicado: (2010)

Liposomal Amphotericin B and Leishmaniasis: Dose and Response
por: Sundar, Shyam, et al.
Publicado: (2010)

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Disseminated tegumentary leishmaniasis refractory to liposomal amphotericin B treatment
por: Borges, Ana Flávia, et al.
Publicado: (2021)

Exploring global and country-level barriers to an effective supply of leishmaniasis medicines and diagnostics in eastern Africa: a qualitative study
por: Sunyoto, Temmy, et al.
Publicado: (2019)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea
por: Guery, Romain, et al.
Publicado: (2017)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

962. Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing
por: Aronson, Naomi E, et al.
Publicado: (2018)

Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis
por: Ren, Danfeng, et al.
Publicado: (2021)

Determinants of Visceral Leishmaniasis: A Case-Control Study in Gedaref State, Sudan
por: Nackers, Fabienne, et al.
Publicado: (2015)

Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B
por: Kirchberger, Michael Constantin, et al.
Publicado: (2019)

Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2017)

Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
por: Kosaka, Atsushi, et al.
Publicado: (2020)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
por: Ramos, Guilherme S., et al.
Publicado: (2022)

Liposomal amphotericin B—the present
por: Maertens, J, et al.
Publicado: (2022)

Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022)

Liposomal amphotericin B—the future
por: Hoenigl, M, et al.
Publicado: (2022)

Control of visceral leishmaniasis in East Africa: fragile progress, new threats
por: Dahl, Elin Hoffmann, et al.
Publicado: (2021)

Validation of Two Rapid Diagnostic Tests for Visceral Leishmaniasis in Kenya
por: Mbui, Jane, et al.
Publicado: (2013)

Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines
por: van Griensven, Johan, et al.
Publicado: (2014)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

New insights into leishmaniasis in the immunosuppressed
por: Akuffo, Hannah, et al.
Publicado: (2018)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

Anticipating visceral leishmaniasis epidemics due to the conflict in Northern Ethiopia
por: Boodman, Carl, et al.
Publicado: (2023)

Visceral Leishmaniasis and HIV Coinfection in East Africa
por: Diro, Ermias, et al.
Publicado: (2014)

Burden of Visceral Leishmaniasis in Villages of Eastern Gedaref State, Sudan: An Exhaustive Cross-Sectional Survey
por: Mueller, Yolanda Kathrin, et al.
Publicado: (2012)

Liposomal Amphotericin B Treatment and the Leishmaniases
por: Berman, Jonathan
Publicado: (2019)

First case of pulmonary tuberculosis and visceral leishmaniasis coinfection successfully treated with antituberculosis drug and liposomal amphotericin B
por: Hasnain, Md Golam, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mi8402unegpoisu5mt03lsnhhq